[go: up one dir, main page]

WO2001091699A3 - Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways - Google Patents

Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways Download PDF

Info

Publication number
WO2001091699A3
WO2001091699A3 PCT/US2001/017358 US0117358W WO0191699A3 WO 2001091699 A3 WO2001091699 A3 WO 2001091699A3 US 0117358 W US0117358 W US 0117358W WO 0191699 A3 WO0191699 A3 WO 0191699A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
identifying agents
kinase pathways
pten function
Prior art date
Application number
PCT/US2001/017358
Other languages
French (fr)
Other versions
WO2001091699A2 (en
Inventor
Donald L Durden
Original Assignee
Advanced Res & Tech Inst
Donald L Durden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Res & Tech Inst, Donald L Durden filed Critical Advanced Res & Tech Inst
Priority to AU2001265137A priority Critical patent/AU2001265137B2/en
Priority to EP01939641A priority patent/EP1289472A4/en
Priority to AU6513701A priority patent/AU6513701A/en
Priority to CA002410514A priority patent/CA2410514A1/en
Publication of WO2001091699A2 publication Critical patent/WO2001091699A2/en
Publication of WO2001091699A3 publication Critical patent/WO2001091699A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
PCT/US2001/017358 2000-05-30 2001-05-30 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways WO2001091699A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001265137A AU2001265137B2 (en) 2000-05-30 2001-05-30 Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
EP01939641A EP1289472A4 (en) 2000-05-30 2001-05-30 COMPOSITIONS AND METHODS FOR IDENTIFYING MODULATORS OF PTEN FUNCTION AND PI-3 KINASE MECHANISMS
AU6513701A AU6513701A (en) 2000-05-30 2001-05-30 Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
CA002410514A CA2410514A1 (en) 2000-05-30 2001-05-30 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20843700P 2000-05-30 2000-05-30
US60/208,437 2000-05-30
US27416701P 2001-03-08 2001-03-08
US60/274,167 2001-03-08

Publications (2)

Publication Number Publication Date
WO2001091699A2 WO2001091699A2 (en) 2001-12-06
WO2001091699A3 true WO2001091699A3 (en) 2002-12-27

Family

ID=26903194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/017358 WO2001091699A2 (en) 2000-05-30 2001-05-30 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways

Country Status (5)

Country Link
US (6) US6777439B2 (en)
EP (1) EP1289472A4 (en)
AU (2) AU2001265137B2 (en)
CA (1) CA2410514A1 (en)
WO (1) WO2001091699A2 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482795B1 (en) * 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US20020142982A1 (en) * 1999-09-02 2002-10-03 Timothy Hla Method for regulating angiogenesis
AU2003264036A1 (en) * 2002-08-08 2004-03-03 Vanderbilt University Pi3k antagonists as radiosensitizers
EP1615639A2 (en) * 2003-04-03 2006-01-18 Semafore Pharmaceuticals, Inc. Targeted bone marrow protection agents
US20080299589A1 (en) * 2003-05-11 2008-12-04 The Regents Of The University Of California Methods and Materials for Examining the P13k/Akt Pathway in Gliomas and Prostate Cancers
CA2524148A1 (en) * 2003-05-14 2005-01-13 Exelixis, Inc. Mptens as modifiers of the pten/igf pathway and methods of use
US8273536B2 (en) * 2003-06-19 2012-09-25 Exelixis, Inc. Marks as modifers of the PTEN pathway and methods of use
EP1633880A4 (en) * 2003-06-19 2006-11-08 Exelixis Inc Mptens as modifiers of the pten/igf pathway and methods of use
WO2005017123A2 (en) * 2003-08-14 2005-02-24 Exelixis, Inc. Mptens as modifiers of the pten pathway and methods of use
EP1756137A4 (en) * 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
WO2005090992A2 (en) * 2004-03-12 2005-09-29 Exelisis, Inc. Mptens as modifiers of the pten pathway and methods of use
WO2005089169A2 (en) * 2004-03-12 2005-09-29 Exelixis, Inc. Mptens as modifiers of the pten pathway and methods of use
US20070203098A1 (en) * 2004-04-06 2007-08-30 Semafore Pharmaceuticals, Inc. Pten Inhibitors
US20060030536A1 (en) * 2004-04-09 2006-02-09 University Of South Florida Combination therapies for cancer and proliferative angiopathies
AU2005258149A1 (en) * 2004-06-21 2006-01-05 Exelixis, Inc. PGDs as modifiers of the PTEN pathway and methods of use
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2006099185A2 (en) * 2005-03-10 2006-09-21 Exelixis, Inc Brsk1s as modifiers of the pten/akt pathway and methods of use
RU2443441C2 (en) * 2005-03-11 2012-02-27 Зеняку Когио Кабусикикайся Immunodepressant and anticancer drug containing heterocyclic compound as active ingredient
US20110135629A1 (en) * 2005-06-20 2011-06-09 Exelixis, Inc. EYA2S As Modifiers of the PTEN/AKT Pathway and Methods of Use
US7576191B2 (en) * 2005-09-13 2009-08-18 Vanderbilt University Tumor suppressor Killin
US20080032960A1 (en) 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
EP2215471B1 (en) 2007-10-29 2012-02-08 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
MX2010007419A (en) 2008-01-04 2010-11-12 Intellikine Inc Certain chemical entities, compositions and methods.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5788316B2 (en) 2008-07-08 2015-09-30 インテリカイン， エルエルシー Kinase inhibitors and methods of use
JP5731978B2 (en) 2008-09-26 2015-06-10 インテリカイン， エルエルシー Heterocyclic kinase inhibitor
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
MX2011008695A (en) * 2009-02-17 2011-10-14 Univ Columbia EXTRACELLULAR IDENTIFICATION OF THE LONG PEPTIDE OF THE TENSIN HOMOLOGY THAT CAN BE USED TO TREAT TUMORS.
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
CN101938880B (en) * 2009-06-30 2014-09-10 通用电气公司 ballast with end-of-life protection for one or more lamps
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
EP2504452A4 (en) * 2009-11-23 2014-06-11 Univ Ohio State Res Found SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (en) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AR084824A1 (en) 2011-01-10 2013-06-26 Intellikine Inc PROCESSES TO PREPARE ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONAS
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc Combination of kanase inhibitors and uses thereof
DK2691384T3 (en) 2011-03-28 2017-01-16 Mei Pharma Inc (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2873769A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating hemoglobin gene family expression
AU2013262706A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating PTEN expression
CA2873779A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
EP2850186B1 (en) 2012-05-16 2018-12-19 Translate Bio MA, Inc. Compositions and methods for modulating smn gene family expression
CN104583401A (en) 2012-05-16 2015-04-29 Rana医疗有限公司 Compositions and methods for modulating ATP2A2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US8903993B2 (en) * 2012-06-01 2014-12-02 International Business Machines Corporation Performance analysis using anonymous aggregated data
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California MODULATION OF IRE1
MX375194B (en) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc TREATMENT OF CANCER USING PI3 KINASE ISOFORM MODULATORS.
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
PT3119397T (en) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US11624093B2 (en) 2014-04-24 2023-04-11 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3212824A4 (en) 2014-10-30 2018-08-08 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
AU2015346371A1 (en) * 2014-11-11 2017-04-27 Western University Of Health Sciences Isoform-specific calpain inhibitors, methods of identification, and uses thereof
US10724097B2 (en) 2014-12-01 2020-07-28 University Of South Florida Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
CN114230571B (en) 2015-09-14 2025-07-08 无限药品股份有限公司 Solid forms of isoquinolinones, methods of making, compositions comprising, and methods of using the same
US10869908B2 (en) 2016-02-29 2020-12-22 The Johns Hopkins University Inducing cell death by hyperactivation of motility networks
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190033526A (en) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 Combination therapy
CN117860758A (en) 2017-05-23 2024-04-12 梅制药公司 Combination therapy
CN109022461B (en) 2017-06-08 2022-01-14 中山大学附属第一医院 Upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and application of encoded polypeptide thereof
CA3072476A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy
CN111521810B (en) * 2019-02-02 2024-06-21 中国科学院上海药物研究所 Cancer patients stratified according to spleen tyrosine kinase
CN112522314A (en) * 2020-12-11 2021-03-19 山东新医学中西医结合医学研究院有限公司 Method for constructing high-expression PTEN vector and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
CA2133815A1 (en) * 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) * 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
AU6653698A (en) * 1997-02-07 1998-08-26 Trustees Of Columbia University In The City Of New York, The Use of the p-ten suppressor gene in diagnosis and treatment of cancer
WO1999002704A2 (en) * 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Dual specifically phosphatase and methods of use
CA2301199C (en) * 1997-08-26 2013-02-05 Myriad Genetics, Inc. A tumor suppressor designated ts10q23.3
US7067109B1 (en) * 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6020199A (en) 1999-07-21 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of PTEN expression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HUANG ET AL.: "PTEN affects cell size, cell proliferation and apoptosis during drosophila eye development", DEVELOPMENT, vol. 126, no. 23, December 1999 (1999-12-01), pages 5365 - 5372, XP002956411 *
LEE ET AL.: "Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association", CELL, vol. 99, 29 October 1999 (1999-10-29), pages 323 - 334, XP002956412 *
LI ET AL.: "A family of putative tumor suppressors is structurally and functionally conserved in humans and yeast", JBC, vol. 272, no. 47, 21 November 1997 (1997-11-21), pages 29403 - 29406, XP002159206 *
LI ET AL.: "Deficiency of PTEN accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice", BMC MOL. BIOL., vol. 2, no. 1, 23 January 2001 (2001-01-23), pages 1 - 9, XP002956421, Retrieved from the Internet <URL:http//www.biomedcontrol.com/1471-2199/2/2> *
LI ET AL.: "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer", SCIENCE, vol. 275, 28 March 1997 (1997-03-28), pages 1943 - 1947, XP002910791 *
LI ET AL.: "PTEN/MMAC1/TEP1 suppresses the tumorgenicity and induces G1 cell cycle arrest in human glioblastoma cells", PROC. NATL. ACAD. SCI. USA, vol. 95, December 1998 (1998-12-01), pages 15406 - 15411, XP002956409 *
SUN ET AL.: "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-triphosphate and akt/protein kinase B signaling pathway", PROC. NATL. ACAD. SCI. USA, vol. 96, May 1999 (1999-05-01), pages 6199 - 6204, XP002956410 *

Also Published As

Publication number Publication date
US20120253020A1 (en) 2012-10-04
US20050032727A1 (en) 2005-02-10
US8163691B2 (en) 2012-04-24
WO2001091699A2 (en) 2001-12-06
US20090162338A1 (en) 2009-06-25
AU6513701A (en) 2001-12-11
US7745485B2 (en) 2010-06-29
US20020150954A1 (en) 2002-10-17
US20040142395A1 (en) 2004-07-22
AU2001265137C1 (en) 2001-12-11
AU2001265137B2 (en) 2007-06-14
US7470721B2 (en) 2008-12-30
EP1289472A2 (en) 2003-03-12
US6777439B2 (en) 2004-08-17
US20100286141A1 (en) 2010-11-11
EP1289472A4 (en) 2004-09-08
CA2410514A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
WO2001091699A3 (en) Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2003035617A3 (en) Derivatives of uk-2a
AU2001237041A1 (en) Kinase inhibitors
EP1192945A3 (en) Use of an estrogen agonist/antagonist for treating osteoarthritis
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
WO2003045840A3 (en) Mesoporous materials and methods
ZA200202985B (en) Tyrosine kinase inhibitors.
WO2000028090A3 (en) Diagnostic assay for cancer
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU2001292802A1 (en) Genetic markers for tumors
AU2001282248A1 (en) Device for controlling an identity document or the like
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AUPR279101A0 (en) Protein kinase signalling
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
WO2001009384A3 (en) Serial analysis of genetic alterations
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU6279500A (en) Epothilone compositions
AU2002241720A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2002232521A1 (en) Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
WO2002057313A8 (en) Receptor-binding compounds and methods for identifying them
GB0101686D0 (en) Cyclin dependent kinase inhibitors
WO2002034204A3 (en) Calcilytic compounds
WO2002028432A3 (en) Stem cell-based methods for preventing and treating tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2410514

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001265137

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001939641

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2001939641

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001265137

Country of ref document: AU